Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

May 9, 2024

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 22 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Brittany Morgan, and I'll be serving as your conference operator for today. I'd like to welcome all of you to the 2024 first quarter earnings conference call for Cronos Group. This call is being recorded as of today. Right now, I'd like to hand things over to Shayne Laidlaw from Investor Relations. Shayne, please go ahead.

Shayne Laidlaw

executive
#2

Thanks, Brittany, and thanks to everyone for being with us today as we go over Cronos' financial and business results for the first quarter of 2024. With me today are Mike Gorenstein, our Chairman, President, and CEO, and James Holm, our CFO. This morning Cronos put out a news release announcing our financial results, and it's filed on our EDGAR and SEDAR profile. That information, along with the prepared remarks, will also be posted on our website in the Investor Relations section. Before handing the call to Mike, I want to remind you that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Such forward-looking statements rest on management's current expectations and assumptions, which are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings available on our website, and any forward-looking statements made during this call are qualified in their entirety by those materials. Information about non-GAAP financial measures, including reconciliations to US GAAP, is also available in our earnings materials on our website. Finally, throughout this conference call we will be making statements regarding market share information, and unless otherwise stated, all market share data is provided by Hifyre.

Shayne Laidlaw

executive
#3

Prepared remarks are what we'll deliver first, and after that we'll open things up for questions and answers. So with that said, I'll turn things over to Mike Gorenstein, Cronos' Chairman, President, and CEO.

Mike Gorenstein

executive
#4

Thank you, Shane, and good morning to all of you. We've gotten off to a robust beginning this year, highlighted by revenue expansion of 30% compared with the prior year, driven by share gains in Canada and a recovery in Israeli sales, along with better gross margin and lower operating expenses resulting from the full realization of the savings we put in place in 2023, and we are well on track to deliver incremental savings of $5 million-$10 million in 2024. The team's steady, unrelenting dedication to growing the top line while at the same time improving operational efficiency has set Cronos up for success in 2024 and beyond. I'd like to spend a moment on the cannabis market and how our brands are positioned. Much of the cannabis market today is defined by products launched to attract the widest possible range of consumers on the basis of price, instead of forging a strong bond with a targeted consumer segment. Absent that strong consumer connection built through a targeted approach, we've observed numerous brands ceding share to more focused offerings. With Spinach, we were highly deliberate about addressing specific consumer needs, and we believe that was key to our success. That approach helped us succeed in establishing Spinach as the number two brand in Canada. We introduced Spinach in Canada at the end of 2018, and from then on, the team has worked diligently to deliver thoughtful innovations to market across a range of categories.

Mike Gorenstein

executive
#5

I couldn't be prouder of this team and everything we've accomplished. We're using Spinach's success as a model for the rest of our portfolio, beginning with Lord Jones. We took Lord Jones back to its adult-use origins and introduced it in Canada, targeting a tighter set of premium categories where we believe brand share will hold up better and travel across borders. After kicking things off with hash infused pre-rolls in Q4 2023, we broadened the lineup in Q1 to add Chocolate Fusions and Live Resin Vapes, which are off to a strong start since launch. We keep extending the footprint of Peace Naturals, our leading international brand. Drawing on our best-in-class genetics and high-quality cultivation, we've introduced strains like Wedding Cake and GMO Cookies into Israel, Germany, Australia, and now the U.K. By deploying the Peace Naturals brand in each new market we enter, we keep solidifying our flower products as market leaders and preparing the ground for the moment regulations permit us to launch borderless products like edibles and vapes. Let's take a closer look at how our brands are doing in market. Spinach's strength spans a range of product categories—particularly flower, edibles, and vapes, where we hold top three share positions.

Mike Gorenstein

executive
#6

Our top products have delivered outstanding results — like GMO Cookies flower, Sours by Spinach edibles, and the new flavor-forward 1.2-gram vapes — and they're generating substantial traction in the market. During Q1, Spinach kept up its momentum in dried flower, holding the number one brand position with 6.5% of retail sales. Behind that success are years of genetic breeding and R&D investment, including tissue culture and best-in-class large-scale cultivation through our JV, Cronos GrowCo. We introduced new flower strains and formats during the quarter, among them ASG in 28 grams and Alien Kush in 3.5 grams, and we're continuing to develop additional strains for launch that build on this lead. We also brought out a new brand built specifically for the Quebec market, called Sōnic, which will offer high-quality flower products aimed at meeting what consumers in that market are asking for. In edibles, Spinach held 14.4% market share in Q1. Our emphasis on creating innovative strategies and products within this category has played a decisive role in getting us here. The standout addition to our lineup is Fully Blasted Sours, a high-potency single-pack 10-milligram THC gummy, which picked up early momentum in Q1, and the early sales we've seen so far are encouraging. With non-compliant edibles exiting the market once more and our competitive one-pack 10-milligram gummy now introduced, we're confident the products we're bringing to market are the right ones.

Mike Gorenstein

executive
#7

In addition to our Spinach brand, we introduced Lord Jones Chocolate Fusions, a bite-sized chocolate that delivers a lively multi-textured experience. We think Chocolate Fusions will define the category, and we're eager to bring it into additional retail doors in the months ahead. On the vape side, Spinach held onto our number 3 market position while picking up share versus the prior period, and we now account for 7.6% of retail sales in that category. Feedback on our new and improved Spinach 1.2-gram vapes has been positive, which further strengthens both our standing in the market and our growth in this category. We also added two new Spinach all-in-one vapes: Pineapple Paradise and Blueberry Dynamite. Within the Lord Jones family, we introduced Lord Jones Live Resin Vapes in January in two different hardware formats. The lineup offers versatile sizes — a half-gram trial size, the convenience of a very sleek all-in-one device, and a 1-gram stock-up size as a 510-thread cartridge — serving both enthusiasts and newcomers to the category. Our focus is on building market share in the pre-roll category, and we keep investing heavily in product development and R&D there. We've introduced a number of new flavor-forward infused pre-roll offerings under the Spinach brand, along with a multi-pack. The Spinach Fully Charged Party Pack combines infused pre-rolls at 40%+ THC, and it includes the finest cold-filtered cannabis extract plus a kief coating.

Mike Gorenstein

executive
#8

Our hash-infused pre-roll sold under the Lord Jones brand has turned into a fan favorite — and it's my personal favorite product. We stay focused on leading in every category where we compete, and that's still the North Star guiding what we do in pre-rolls. Shifting to international markets: our business in Israel bounced back strongly from Q4, which the war affected, and Q1 delivered the highest revenue quarter in Israel since Q4 of 2022. The Israel team has put in a huge amount of work refining their processes and their approach to the market, which produced both higher volumes and better average selling prices sequentially. Our strength in Israel also comes from our GMO and Wedding Cake genetics, developed in-house, which have driven the Peace Naturals brand to a leading position in the market it enters. In April, we named Adam Wagner as SVP, Head of Cronos Israel, where he had been VP of Finance. Adam brings substantial finance and operational experience across both public and private companies to this leadership role. We're already seeing a positive impact from his leadership and look forward to his stewardship of the business. We're confident that our team's approach to the Israeli market is as good as ever, and I believe that under their leadership, we will keep refining and improving over time.

Mike Gorenstein

executive
#9

We're especially enthusiastic about the growth potential we see in Germany. Recent changes to legislation there have driven meaningful incremental growth in that market and opened up opportunities to responsibly market medical cannabis products, something that wasn't allowed under earlier rules. We remain dedicated to supplying high-quality cannabis products and to cultivating our partnership with Cansativa. We're also pleased to share another international milestone from earlier this week: our first shipment into the UK medical market. Our aim is to build our Peace Naturals brand into a leading medical brand for UK patients, just as we've done in Israel and Germany. International revenue can be uneven from one quarter to the next. So while we recorded no revenue in Germany or Australia in Q1 after our initial load-in, we're very happy with the in-market sell-through during the quarter. We feel confident about where our international revenue is headed in 2024, which reflects our dedication to expanding globally and diversifying revenue. Our joint venture, GrowCo, keeps performing exceptionally well, showing strong results that match our expectations. GrowCo reported preliminary unaudited revenue to us of roughly $5.1 million from non-Cronos customers in the first quarter. In addition, the credit facility Cronos previously extended to GrowCo presently carries $67.1 million outstanding, after principal repayments of $1.2 million in Q1.

Mike Gorenstein

executive
#10

GrowCo also paid $1.4 million in interest during Q1. The strong financial results from GrowCo — which generate equity pickup, interest payments, and repayment of a loan to Cronos — are an essential part of our broader financial picture. Now to the U.S.: last week, according to media reports, the DEA intends to adopt the HHS recommendation to move cannabis to Schedule III; that proposal, which the White House Office of Management and Budget still has to review, would not make cannabis federally legal for adult use, but it represents a dramatic change in how the plant is classified. We believe incremental progress is excellent for the industry, and this is movement in the right direction. The wins this quarter came from our unwavering focus on assembling a portfolio of borderless products backed by strategic infrastructure and global partnerships. Our long-term plan to put money into branded innovation aimed at specific consumer needs, or else stay asset light, is delivering, and we've had a tremendous beginning to our 2024 fiscal year. Together, these efforts and an industry-leading balance sheet position us well to grow in our existing markets and to execute in any new market we choose to enter. With that, I'll hand things over to James, who will walk you through our financials.

James Holm

executive
#11

Thanks, Mike. Good morning, everyone. I'll now walk through our first quarter 2024 results compared with the prior year period. The company reported consolidated net revenue of $25.3 billion, a 30% increase from the prior year period. Constant currency consolidated net revenue increased by 31% to $25.5 million. The revenue increase was primarily driven by higher cannabis flower and extract sales in Canada, and higher cannabis flower sales in Israel. Gross profit in the first quarter was $4.5 million, equating to an 18% gross margin, representing a $1.5 million improvement in gross profit and a 270 basis point improvement in gross margin from the prior year period. The increase was primarily driven by higher sales in cannabis flower and extracts in Canada and higher cannabis flower sales in Israel. The improvement in top line was coupled with numerous supply chain efficiencies, such as favorable labor and overhead costs, as well as lower inventory variances, all culminating to drive a material improvement in gross margin from Q4 2023. Consolidated Adjusted EBITDA in the first quarter was negative $10.7 million, representing a $5 million improvement from the prior year period. The improvement was primarily driven by a decline in general and administrative and research and development expenses and an improvement in gross profit.

James Holm

executive
#12

After beating our savings target last year, we're making solid progress toward the 2024 objective of an incremental $5-$10 million in savings. Beyond capturing operational efficiencies and getting the most out of our cash, we collected an interest payment of roughly $1.4 million on the GrowCo senior secured loan along with a principal repayment of about $1.2 million — altogether, GrowCo paid Cronos approximately $2.7 million in cash during Q1. Because we hold the strongest balance sheet in the cannabis sector, we can make prudent strategic bets while staying firmly committed to cutting cash burn. On the balance sheet, the company finished the quarter with about $855 million in cash and cash equivalents. Turning to the cash flow statement, operating cash flow came in at negative roughly $2.2 million. That compares with negative approximately $47.7 million a year earlier, a period that included a cash outflow of about $33 million tied to the Altria warrant relinquishment. Free cash flow — operating cash flow minus CapEx — was negative $4.2 million. Against negative approximately $48.5 million in the prior year period, that's a substantial improvement. There are plenty of wins we can point to this quarter.

James Holm

executive
#13

We’ve been gaining market share, reducing OpEx, and optimizing both the balance sheet and cash flow — and we’re reaffirming guidance that the net change in cash, which we define as cash plus cash equivalents plus short-term investments, is expected to be positive in 2024. Reflecting on how far we’ve come, I share Mike’s confidence in where our business is headed and in how ready we are to enter new markets as they open up. With that, I’ll turn it over to questions.

Operator

operator
#14

Thank you. We'll now move into a question-and-answer session. Just a reminder that to ask a question, you'll need to press star one one on your telephone and then wait for your name to be announced. If you'd like to withdraw your question, please press star one one again. Please note that every analyst is permitted to ask one question and one follow-up question. Please stand by while we compile the Q&A roster. Our first question comes from the line of John Zamparo with CIBC. Your line is now open.

John Zamparo

analyst
#15

Thanks. Morning, everyone. I'd like to begin with the rescheduling development, and I suspect I already know what you'll say, but I'll pose the question regardless. Imagine we jump ahead to roughly November and a formal rescheduling does come through — with all approvals in place. I'm curious: if nothing else shifts, how would that affect Cronos Group?

Mike Gorenstein

executive
#16

Absolutely. Morning, John, and thank you. I mean, I'd say this is definitely quite exciting and a significant move in the right direction, though rescheduling itself is a very wide-ranging concept, and the devil will be in the details, in my view. So there are going to be plenty of possible opportunities as well as restrictions. We're looking at a lot of plans, but I think we truly need to see the specifics before saying anything about precisely how we'd go after a U.S. strategy under whatever new framework might emerge.

John Zamparo

analyst
#17

All right, understood. Now shifting to Canada: across the whole industry, growth has been weaker so far this year. Your brands don't appear to be affected by that. Still, I'm curious what you think is behind the industry's slowdown. Clearly pricing plays a part, but do you sense consumers are continuing to trade down? After all, this industry has always been fiercely competitive on price and highly price-sensitive. I'm wondering how the industry could deliver more value, and what effect that has on your strategy?

Mike Gorenstein

executive
#18

Absolutely. For our own brand, we have kept seeing growth. What matters most, I think, is that we have now reached a stage where you are not observing meaningful price compression, at least when it comes to flower. So it really comes down to launching new products, delivering superior quality to the market, and competing against the illicit market. Going back to the prepared remarks, I believe it is about selecting the consumer segments and building something that is narrowly focused on meeting their needs. That is what we will keep doing. It is what we will keep concentrating on, and you will see us—whether through Spinach or Lord Jones—continuing to create great products, and I think that is what will drive our growth.

John Zamparo

analyst
#19

Much appreciated. I'll make sure that gets shared.

Operator

operator
#20

Appreciate it. Give us a second while we bring up the following question. That question is from Matt Bottomley at Canaccord Genuity. Matt, your line is live now.

Matt Bottomley

analyst
#21

Morning, everyone, and thank you for the comments so far. I just want to keep us on the Canadian market for a moment. Many of us have been following retail trends, and as John mentioned, there's some slowing we're seeing in the space. But I'm curious whether you could say more about what you've experienced over the last three months or so with the provincial wholesalers. There's been a lot of hopeful thinking — especially from some of the leading LPs — that maybe it will come to fruition, that the IRS — sorry, I'm in my US mode — the CRA, sort of coming back and really calling some of these old excise tax payables that might reduce the amount of saturation in the space. Are you seeing any tangible change in the competitive profile when you're putting purchase orders in from the provinces, or do you think that's a longer term trend?

Mike Gorenstein

executive
#22

Okay, so I believe the CRA beginning to garnish certain payments from LPs that aren’t paying their CRA tax — or rather, not paying the excise taxes — is a move in the right direction and genuinely helps make things fairer, though more action is certainly required, in my view. It’s difficult to pin down precisely what is behind some of these trends. You know, I’d say supply is beginning to dry up, but perhaps what matters more than the CRA is likely the reduced supply stemming from all those facility shutdowns we’ve witnessed over the past few years. And on top of that, I think international demand has increased, and that is probably beginning to pull some product as well. So, as you can see, we have definitely seen growth, but I think many factors are driving that, and the CRA would only be one of them.

Matt Bottomley

analyst
#23

All right, got it. Then I have one more question, this one about the international side rather than Canada. Clearly, for any Canadian producer that ships abroad, this isn't anything new. There's a certain lumpiness whenever product ebbs and flows. You've seen some fairly large swings in Israel, and I grasp some of the dynamics at play there. But is there any forward-looking commentary you could offer, perhaps as a percentage of your total revenues, looking ahead over a full 12 months, on how international might compare with what it has been historically?

Mike Gorenstein

executive
#24

Sure. You know, I'd prefer not to provide percentage guidance. I'll simply note that, in my view, Israel will be less uneven for us, because of how we report on Israel compared with other markets, since it's a core market for us. We have, you know, sales and manufacturing there. What we're really reporting is sell-through, so that differs from, say, the UK, Australia, or Germany. But I will say we anticipate significant growth in Germany, given the regulatory change, and it's a market we're extremely excited about. And I think the UK does have a lot of potential to grow in the back half of the year.

Matt Bottomley

analyst
#25

Alright. Appreciate it, Mike.

Operator

operator
#26

Okay, thanks a lot for that. Just a quick reminder for everybody: if you'd like to ask something, press star one one on your phone and hang on until your name gets called out. If you want to take your question back, just hit star one one once more. Keep in mind that each analyst may pose one question plus one follow-up. Please hold on while we put together the Q&A lineup. All right. At this point I'm not seeing any more questions. Thanks for joining today's conference. That brings us to the-

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.